Tivity Health (TVTY) 10-Q 9 May 19 2019 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2019	Apr. 30, 2019
Document And Entity Information [Abstract]
Entity Registrant Name	TIVITY HEALTH, INC.
Entity Central Index Key	0000704415
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Trading Symbol	TVTY
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2019
Entity Common Stock, Shares Outstanding		47,702,306

CONSOLIDATED BALANCE SHEETS (Un

CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 18,788	$ 1,933
Accounts receivable, net	120,800	67,139
Inventories	32,469
Prepaid expenses	13,116	3,655
Income taxes receivable	2,518	720
Other current assets	5,658	4,658
Total current assets	193,349	78,105
Property and equipment, net of accumulated depreciation of $32,927 and $30,711 respectively	47,985	16,341
Right-of-use assets	46,747
Intangible assets, net	975,729	29,049
Goodwill, net	780,351	334,680
Other long-term assets	26,427	23,904
Total assets	2,070,588	482,079
Current liabilities:
Accounts payable	88,083	29,103
Accrued salaries and benefits	8,696	6,512
Accrued liabilities	51,576	42,563
Deferred revenue	16,129	582
Income taxes payable	493
Current portion of debt	44,900	57
Current portion of lease liabilities	14,808
Current portion of long-term liabilities	1,455	2,255
Total current liabilities	226,140	81,072
Long-term debt	1,066,940	30,589
Long-term lease liabilities	35,166
Long-term deferred tax liability	225,039	319
Other long-term liabilities	139	1,098
Stockholders' equity:
Preferred stock $.001 par value, 5,000,000 shares authorized, none outstanding
Common Stock $.001 par value, 120,000,000 shares authorized, 47,679,712 and 41,049,418 shares outstanding, respectively	47	41
Additional paid-in capital	491,548	347,487
Retained earnings	53,751	49,655
Treasury stock, at cost, 2,254,953 shares in treasury	(28,182)	(28,182)
Total stockholders' equity	517,164	369,001
Total liabilities and stockholders' equity	$ 2,070,588	$ 482,079

CONSOLIDATED BALANCE SHEETS (_2

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Statement Of Financial Position [Abstract]
Accumulated depreciation	$ 32,927	$ 30,711
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	120,000,000	120,000,000
Common stock, shares outstanding (in shares)	47,679,712	41,049,418
Treasury stock (in shares)	2,254,953	2,254,953

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income Statement [Abstract]
Revenues	$ 214,094	$ 149,930
Cost of revenue (exclusive of depreciation and amortization of $2,008 and $975, respectively, included below)	140,338	105,396
Marketing expenses	24,149	2,887
Selling, general and administrative expenses	27,186	8,577
Depreciation and amortization	3,582	1,123
Restructuring and related charges	1,591
Operating income	17,248	31,947
Interest expense	7,666	3,454
Income before income taxes	9,582	28,493
Income tax expense	5,368	7,157
Net income	$ 4,214	$ 21,336
Earnings per share:
Basic	$ 0.10	$ 0.54
Diluted	$ 0.10	$ 0.49
Comprehensive income	$ 4,214	$ 21,336
Weighted average common shares and equivalents:
Basic	42,745	39,783
Diluted	43,183	43,589

CONSOLIDATED STATEMENTS OF OP_2

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income Statement [Abstract]
Cost of services, depreciation and amortization	$ 2,008	$ 975

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Statement Of Income And Comprehensive Income [Abstract]
Net income	$ 4,214	$ 21,336
Comprehensive income	$ 4,214	$ 21,336

CONSOLIDATED STATEMENT OF CHANG

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Retained Earnings (Accumulated Deficit)	Treasury Stock
Balance at Dec. 31, 2017	$ 271,953	$ 40	$ 349,243	$ (49,148)	$ (28,182)
Comprehensive income	21,336			21,336
Exercise of stock options	770		770
Tax withholding for share-based compensation	(894)		(894)
Share-based employee compensation expense	1,410		1,410
Balance at Mar. 31, 2018	294,575	40	350,529	(27,812)	(28,182)
Balance at Dec. 31, 2018	369,001	41	347,487	49,655	(28,182)
Comprehensive income	4,214			4,214
Issuance of Common Stock in connection with Merger	132,838	6	132,832
Share-based compensation replacement awards related to Merger and attributable to pre-combination services	9,107		9,107
Exercise of stock options	234		234
Tax withholding for share-based compensation	(342)		(342)
Share-based employee compensation expense	2,359		2,359
Other	(247)		(129)	(118)
Balance at Mar. 31, 2019	$ 517,164	$ 47	$ 491,548	$ 53,751	$ (28,182)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash flows from operating activities:
Net income	$ 4,214	$ 21,336
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	3,582	1,123
Amortization and write-off of deferred loan costs	900	522
Amortization of debt discount	389	2,044
Share-based employee compensation expense	2,359	1,410
Deferred income taxes	4,355	7,090
Increase in accounts receivable, net	(31,123)	(12,712)
Decrease in inventory	6,025
Decrease in other current assets	168	2,037
Increase (decrease) in accounts payable	6,555	(916)
Decrease in accrued salaries and benefits	(767)	(9,007)
Increase (decrease) in other current liabilities	5,576	(1,185)
Increase in deferred revenue	2,309
Other	660	625
Net cash flows provided by operating activities	5,202	12,367
Cash flows from investing activities:
Acquisition of property and equipment	(3,898)	(1,946)
Business acquisitions, net of cash acquired	(1,062,818)
Net cash flows used in investing activities	(1,066,716)	(1,946)
Cash flows from financing activities:
Proceeds from issuance of long-term debt	1,274,925	8,400
Payments of long-term debt	(167,134)	(8,793)
Payments related to tax withholding for share-based compensation	(342)	(894)
Exercise of stock options	234	771
Deferred loan costs	(30,189)
Change in cash overdraft and other	891	378
Net cash flows provided by (used in) financing activities	1,078,385	(138)
Effect of exchange rate changes on cash	(16)	69
Net increase in cash and cash equivalents	16,855	10,352
Cash and cash equivalents, beginning of period	1,933	28,440
Cash and cash equivalents, end of period	$ 18,788	$ 38,792

Basis of Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Basis of Presentation	1. Basis of Presentation Our financial statements and accompanying notes are prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”). In our opinion, the accompanying consolidated financial statements of Tivity Health ® ® We have reclassified certain items in prior periods to conform to current classifications. Following the acquisition of Nutrisystem, we organize and manage our operations within two reportable segments, based on the types of products and services they offer: Healthcare and Nutrition. The Healthcare segment is comprised of our legacy business and includes SilverSneakers senior fitness, Prime Fitness and WholeHealth Living TM ® and the South Beach Diet ® products. We have omitted certain financial information that is normally included in financial statements prepared in accordance with U.S. GAAP but that is not required for interim reporting purposes. You should read the accompanying consolidated financial statements in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2018.

Business Combinations

Business Combinations	3 Months Ended
	Mar. 31, 2019
Business Combinations [Abstract]
Business Combinations	2. Business Combinations On December 9, 2018, we entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Nutrisystem, a provider of weight management products and services, and Sweet Acquisition, Inc., a wholly-owned subsidiary of Tivity Health (“Merger Sub”). The Merger Agreement provided that Merger Sub would merge with and into Nutrisystem, with Nutrisystem surviving as a wholly-owned subsidiary of Tivity Health (the “Merger”). The Merger was completed o except for certain excluded shares, each share of Nutrisystem common stock outstanding immediately prior to Closing was converted into the right to receive $38.75 in cash, without interest, and 0.2141 of a share of Tivity Health Common Stock (“Exchange Ratio”) (with cash payable in lieu of any fractional shares). Nutrisystem shares excluded from the conversion were those shares held by Nutrisystem as treasury stock and shares with respect to which appraisal rights have been properly exercised in accordance with the General Corporation Law of the State of Delaware. The acquisition of Nutrisystem enables us to offer, at scale, an integrated portfolio of fitness, nutrition and social engagement solutions to support overall health and wellness and to address weight management, chronic conditions, and social isolation. The fair value of consideration transferred at Closing was $1.3 billion (“Merger Consideration”), which includes cash consideration, the fair value of the stock consideration, and the fair value of the consideration for Nutrisystem equity awards assumed by Tivity Health that related to pre-combination services (see Note 8). (In thousands) Cash paid for outstanding Nutrisystem shares (1) $ 1,138,143 Value of Tivity Health Common Stock issued in the merger (2) 132,838 Value of Nutrisystem stock options (3) 6,020 Value of Tivity Health replacement awards attributable to pre-combination service (4) 9,107 Total Merger Consideration $ 1,286,108 (1) Represents the total cash paid to former Nutrisystem stockholders as cash consideration. This amount is based on the 29,370,594 shares of Nutrisystem common stock issued and outstanding as of Closing and cash consideration of $38.75 per share, plus cash payable in lieu of fractional shares. (2) Represents the fair value of 6.3 million shares of Tivity Health Common Stock issued for outstanding Nutrisystem shares as stock consideration. This amount is based on (a) 29,370,594 Nutrisystem common shares issued and outstanding as of Closing, times (b) the Exchange Ratio of 0.2141, times (c) $21.12, which is equal to the volume-weighted averages of the trading price per share of our Common Stock for the five consecutive trading days up to and including March 6, 2019. (3) Represents the fair value of the cash consideration paid for the net settlement of approximately 204,000 Nutrisystem stock options vested and outstanding as of the closing date. In accordance with the Merger Agreement, each vested and outstanding Nutrisystem stock option was cancelled, and the holder received a cash payment per option equal to approximately $43.27 minus the applicable exercise price of the stock option. (4) U nvested restricted stock awards and performance stock units held by Nutrisystem employees were assumed by Tivity Health and converted into time-vesting restricted stock awards and time-vesting restricted stock units, respectively (“Replacement Awards”). The value in the table represents the portion of the fair value of the Replacement Awards that relates to pre-combination services. We performed a valuation analysis of the fair market value of Nutrisystem’s assets and liabilities as of Closing. The following table sets forth an allocation of the Merger Consideration to the identifiable tangible and intangible assets acquired and liabilities assumed, with the excess recorded to goodwill. This allocation of the Merger Consideration may be subject to revision if new facts and circumstances arise over the measurement period, which may extend up to one year from Closing. (In thousands) Cash, cash equivalents, and short-term investments $ 81,217 Accounts receivable 22,639 Inventory 38,494 Prepaid expenses and other current assets 12,345 Property and equipment 31,233 Right-of-use assets 22,145 Intangible assets 948,000 Other assets/liabilities 7,161 Accounts payable (58,253 ) Accrued salaries and benefits and other liabilities (8,695 ) Deferred revenue (13,339 ) Lease liabilities (22,145 ) Deferred tax liabilities, net (220,365 ) Total identifiable assets and liabilities acquired $ 840,437 Goodwill (1) 445,671 Total Merger Consideration $ 1,286,108 (1) Goodwill represents the excess of merger consideration over the preliminary fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Nutrisystem and synergies expected to be achieved from the combined operations of Tivity Health and Nutrisystem. We consolidated Nutrisystem’s operating results into our financial statements beginning on March 8, 2019. Refer to Note 16 for revenue and profit recognized from the Nutrition segment during the three months ended March 31, 2019. The following financial information presents the pro forma combined company results as if the acquisition of Nutrisystem had occurred on January 1, 2018: (In thousands) Three Months Ended March 31, 2019 2018 Revenue $ 347,542 $ 360,860 Net loss $ (4,635 ) $ (29,842 ) The above pro forma results are based on assumptions and estimates, which we believe to be reasonable. They are not the operating results that would have been realized had the acquisition actually closed on January 1, 2018 and are not necessarily indicative of our ongoing combined operating results. The pro forma results include adjustments related to purchase accounting, acquisition and integration costs, financing, and amortization of intangible assets. Material non-recurring pro forma adjustments reflected in the pro forma results for the three months ended March 31, 2019 include: (1) the operating results of Nutrisystem from January 1, 2019 to March 7, 2019, (2) acquisition, integration, and restructuring costs decrease of $33.4 million, and (3) income tax expense decrease of $2.7 million (see Note 9). For the three months ended March 31, 2018, material non-recurring pro forma adjustments reflected in the pro forma results include: cost of revenue increase of $2.8 million due to the purchase accounting mark-up of inventory, (2) acquisition, integration, and restructuring costs increase of $38.7 million, and (3) i see Note 9).

Recent Relevant Accounting Stan

Recent Relevant Accounting Standards	3 Months Ended
	Mar. 31, 2019
New Accounting Pronouncements And Changes In Accounting Principles [Abstract]
Recent Relevant Accounting Standards	3. Re c o a d On January 1, 2019, we adopted Accounting Standards Update (“ASU”) We elected to recognize the cumulative effect of initially applying the standard as an adjustment to beginning retained earnings as of January 1, 2019. The significant majority of our leases are classified as operating leases. As of January 1, 2019, we recognized a right-of-use asset of $27.0 million and lease liabilities of $29.7 million. On March 8, 2019, we assumed existing leases from Nutrisystem and recognized additional right-of-use assets and lease liabilities of $22.1 million each. In addition, we elected the following practical expedients available under ASC 842: (1) the package of practical expedients whereby we are not required to reassess upon adoption of ASC 842 (a) whether a contract is or contains a lease, (b) lease classification, and (c) initial direct costs (ASC 842-10-65-1(f)); and (2) the short-term lease measurement and recognition exemption (ASC 842-20-25-2). ASC 842 also requires significant new disclosures about leasing activity In January 2017, the FASB issued ASU No. 2017-04, “Intangibles - Goodwill and Other” (“ASU 2017-04”), which simplifies the subsequent measurement of goodwill by eliminating step two from the goodwill impairment test. ASU 2017-04 is effective for annual and interim impairment tests in fiscal years beginning after December 15, 2019 and is required to be applied prospectively. Early adoption is allowed for annual goodwill impairment tests performed on testing dates after January 1, 2017. We do not anticipate that adopting this standard will have an impact on our consolidated financial statements and related disclosures. In August 2018, the FASB issued ASU No. 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement” (“ASU 2018-13”), which changes the fair value measurement disclosure requirements of ASC 820. ASU 2018-13 is effective for fiscal years beginning on or after December 15, 2019, including interim periods therein, and is generally required to be applied retrospectively, except for certain components that are to be applied prospectively. Early adoption is permitted for any eliminated or modified disclosures. We do not anticipate that adopting this standard will have a material impact on our disclosures. In August 2018, the FASB issued ASU No. 2018-15, “Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract,” which requires implementation costs incurred by customers in cloud computing arrangements to be deferred and recognized over the term of the arrangement, if those costs would be capitalized by the customer in a software licensing arrangement. This standard is effective for annual periods beginning after December 15, 2019, and interim periods within those fiscal years. We do not anticipate that adopting this standard will have a material impact on our consolidated financial statements and related disclosures. In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”), which requires companies to measure credit losses for financial assets held at the reporting date utilizing a methodology that reflects current expected credit losses over the lifetime of such assets. ASU 2016-13 is effective for the Company on January 1, 2020 and is generally required to be applied using the modified retrospective approach, with limited exceptions for specific instruments. We do not anticipate that adopting this standard will have an impact on our consolidated financial statements and related disclosures.

Revenue Recognition

Revenue Recognition	3 Months Ended
	Mar. 31, 2019
Revenue From Contract With Customer [Abstract]
Revenue Recognition	4. Revenue Recognition Beginning in 2018, we account for revenue from contracts with customers in accordance with Accounting Standards Codification (“ASC”) Topic 606. The unit of account in ASC Topic 606 is a performance obligation, which is a promise in a contract to transfer to a customer either a distinct good or service (or bundle of goods or services) or a series of distinct goods or services provided over a period of time. ASC Topic 606 requires that a contract's transaction price, which is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, is to be allocated to each performance obligation in the contract based on relative standalone selling prices and recognized as revenue when or as the performance obligation is satisfied. Healthcare Segment Our Healthcare segment earns revenue from three programs, SilverSneakers® senior fitness, Prime® Fitness and WholeHealth Living TM Except for Prime Fitness, our Healthcare segment’s customer contracts generally have initial terms of approximately three years. Some contracts allow the customer to terminate early and/or determine on an annual basis to which of their members they will offer our programs. The significant majority of Healthcare segment’s customer contracts contain one performance obligation - to stand ready to provide access to our network of fitness locations and fitness programming - which is satisfied over time as services are rendered each month over the contract term. There are generally no performance obligations that are unsatisfied at the end of a particular month. There was no material revenue recognized during the three months ended March 31, 2019 from performance obligations satisfied in a prior period. Our fees within the Our Healthcare segment’s customer contracts include variable consideration, which is allocated to each distinct month over the contract term based on eligible members and/or member visits each month. The allocated consideration corresponds directly with the value to our customers of our services completed for the month. Under the majority of Healthcare segment’s contracts, we recognize revenue each month using the practical expedient available under ASC 606-10-55-18, which provides that revenue is recognized in the amount for which we have the right to invoice. Although we evaluate our financial performance and make resource allocation decisions based upon the results of our two reportable segments, we believe the following information depicts how our Healthcare segment revenues and cash flows are affected by economic factors. The following table sets forth Healthcare revenue disaggregated by program. Revenue from our SilverSneakers program is predominantly contracted with Medicare Advantage and Medicare Supplement plans. (In thousands) Three Months Ended March 31, 2019 2018 SilverSneakers $ 123,024 $ 120,925 Prime Fitness 28,743 24,734 WholeHealth Living 4,575 4,217 Other 185 54 $ 156,527 $ 149,930 Sales and usage-based taxes are excluded from revenues. Nutrition Segment Our Nutrition segment earns revenue from four sources: direct to consumer, retail, QVC and other. Revenue is measured based on the consideration specified in a contract with a customer and excludes any sales incentives and amounts collected on behalf of third parties. As explained in more detail below, revenue is recognized upon satisfaction of the performance obligation by transferring control over a product to a Nutrition segment customer. Direct-mail advertising costs are expensed as incurred. We recognize an asset for the carrying amount of product to be returned and for costs to obtain a contract if the amortization is more than one year in duration. We expense costs to obtain a contract as incurred if the amortization period is less than one year. We sell pre-packaged foods directly to weight loss program participants primarily through the Internet and telephone (referred to as the direct to consumer channel), through QVC (a television shopping network), and select retailers. Pre-packaged foods include both frozen and non-frozen (ready-to-go), shelf-stable products. Products sold through the direct to consumer channel, both frozen and non-frozen, may be sold separately (a la carte) or as part of a packaged monthly meal plan for which customers pay at the point of sale. Products sold through QVC are payable by QVC upon our shipment of the product to the end consumer. For both the direct to consumer channel and QVC, we recognize revenue at a point in time, i.e., at the shipping point. Direct to consumer customers may return unopened ready-to-go products within 30 days after purchase in order to receive a refund or credit. Frozen products are non-returnable and non-refundable unless the order is canceled within 14 days after delivery. Products sold to retailers include both frozen and non-frozen products and are payable by the retailer upon receipt. We recognize revenue at a point in time, i.e., when the retailers take possession of the product. Certain retailers have the right to return unsold products. We account for the shipment of frozen and non-frozen, ready-to-go products as separate performance obligations. The consideration, including variable consideration for product returns, is allocated between frozen and non-frozen products based on their standalone selling prices. The amount of revenue recognized is adjusted for expected returns, which are estimated based on historical data. In addition to our pre-packaged foods, we sell prepaid gift cards through a wholesaler that are redeemable through the Internet or telephone. Prepaid gift cards represent grants of rights to goods to be provided in the future to gift card buyers. The wholesaler has the right to return all unsold prepaid gift cards. The wholesaler’s retail selling price of the gift cards is deferred in the balance sheet and recognized as revenue when we have satisfied our performance obligation, i.e., when a gift card holder redeems the gift card with us. We recognize breakage amounts (the estimated amount of unused gift cards) as revenue, in proportion to the actual gift card redemptions exercised by gift card holders in relation to the total expected redemptions of gift cards. We utilize historical experience in estimating the total expected breakage and period over which the gift cards will be redeemed. Sales and other taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the Company from a Nutrition segment customer are excluded from revenue and presented on a net basis. After control over a product has transferred to a Nutrition segment customer, shipping and handling costs associated with outbound freight are accounted for as a fulfillment cost and are included in revenue and cost of revenue in the accompanying consolidated statements of operations. Revenue from shipping and handling charges was $1.8 million for the three months ended March 31, 2019. The following table sets forth Nutrition segment revenue disaggregated by the source of revenue: (In thousands) Three Months Ended March 31, 2019 Direct to consumer $ 52,654 Retail 4,304 QVC 522 Other 87 $ 57,567 The following table provides information about receivables, contract assets and contract liabilities from contracts with customers: (In thousands) March 31, 2019 Contract assets $ 480 Contract liabilities $ 14,997 The contract assets primarily relate to unbilled accounts receivable and are included as other current assets in the accompanying consolidated balance sheet. The contract liabilities (deferred revenue) primarily relate to sale of prepaid gift cards and unshipped foods, which are deferred until such time as the Company has satisfied its performance obligations. Significant changes in the contract liabilities (deferred revenue) balance during the period are as follows: Three Months Ended March 31, (In thousands) 2019 Revenue recognized that was included in the contract liability (deferred revenue) balance on March 8, 2019 $ (2,752 ) Increases due to cash received for prepaid gift cards sold or unshipped food, excluding amounts recognized as revenue $ 4,409 The following table includes estimated revenue from the prepaid gift cards expected to be recognized in the future related to performance obligations that are unsatisfied (or partially satisfied) at the end of the reporting period: (In thousands) Remaining 2019 $ 10,665 2020 1,303 2021 665 $ 12,633 We apply the practical expedient in subtopic ASC 606-10-50-14 and do not disclose information about remaining performance obligations that have original expected durations of one year or less. We review the reserves for our customer returns at each reporting period and adjust them to reflect data available at that time. To estimate reserves for returns, we consider actual return rates in preceding periods and changes in product offerings or marketing methods that might impact returns going forward. To the extent the estimate of returns changes, we will adjust the reserve, which will impact the amount of revenue recognized in the period of the adjustment. The provision for estimated returns for the three months ended March 31, 2019 The reserve for estimated returns incurred but not received and processed was and has been included in accrued liabilities in the accompanying consolidated balance sheet

Inventories

Inventories	3 Months Ended
	Mar. 31, 2019
Inventory Disclosure [Abstract]
Inventories	5. Inventories Inventories consist principally of packaged food held in external fulfillment locations. We value inventories at the of cost or net realizable value, with cost determined using the first-in, first-out method. We continually assess quantities of inventory on hand to identify excess or obsolete inventory and record a provision for any estimated loss. We estimate the reserve for excess and obsolete inventory primarily on forecasted demand and/or our ability to sell the products, our ability to introduce new products, future production requirements, and changes in consumer behavior. The reserve for excess and obsolete inventory was $1.3 million at March 31, 2019 .

Intangible Assets and Goodwill

Intangible Assets and Goodwill	3 Months Ended
	Mar. 31, 2019
Goodwill And Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	6. Intangible Assets and Goodwill We amortize intangible assets subject to amortization on a straight-line basis over the applicable useful lives of the identifiable assets. In connection with our acquisition of Nutrisystem on March 8, 2019, we recorded the following amounts of intangible assets and goodwill. All of the goodwill was recorded to the Nutrition segment, and none of the goodwill is deductible for tax purposes. (In thousands) Fair Value Estimated Useful Life (in years) Intangible assets subject to amortization: Tradename - South Beach Diet 9,000 15 Customer list 125,000 7 Retail customer relationship 8,000 10 Noncompetition agreements 6,000 5 Subtotal $ 148,000 Intangible assets not subject to amortization: Tradename - Nutrisystem 800,000 n/a Total intangible assets $ 948,000 Goodwill 445,671 n/a In addition, as of March 31, 2019, there was $334.7 million of goodwill and $29 . The change in the carrying amount of goodwill during the three months ended March 31, 2019 was as follows: (In thousands) Balance, January 1, 2019 $ 334,680 Acquisition of Nutrisystem 445,671 Balance, March 31, 2019 $ 780,351

Marketing Expenses

Marketing Expenses	3 Months Ended
	Mar. 31, 2019
Marketing And Advertising Expense [Abstract]
Marketing Expenses	7. Marketing Expenses Marketing expense includes media, advertising production, marketing and promotional expenses and payroll-related expenses, including share-based payment arrangements, for personnel engaged in these activities. For the three months ended March 31, 2019, media expense was $20.3 million. Internet advertising expense is recorded based on either the rate of delivery of a guaranteed number of impressions over the advertising contract term or on the cost per customer acquired, depending upon the terms. All other advertising costs are charged to expense as incurred or the first time the advertising takes place. At March 31, 2019, $1.4 million of costs have been prepaid for future advertisements and promotions. Prior to the acquisition of Nutrisystem, Tivity Health historically classified marketing expenses within cost of revenue and selling, general, and administrative expenses, while Nutrisystem presented marketing expenses in a separate line item. Because marketing expense is material to the combined company and for purposes of comparability, we have reclassified historical Tivity Health marketing expenses to a separate line for the three months ended March 31, 2019 and 2018.

Share-Based Compensation

Share-Based Compensation	3 Months Ended
	Mar. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share-Based Compensation	8 . Share-Based Compensation We currently have h e a e d a d oc n e performance stock units, u h ba a a d a e o l e e o o c l During the three months ended March 31, 2019, we granted the following awards to employees of Nutrisystem in replacement of their unvested equity awards as of Closing (“Replacement Awards”): (i) approximately 258,000 time-vesting restricted stock awards at a fair value of $19.42 per share and (ii) approximately 919,000 time-vesting restricted stock units at a fair value of $19.42 per share. We recognize share-based compensation expense for the market stock units if the requisite service period is rendered, even if the market condition is never satisfied. For the three months ended March 31, 2019, we recognized total share-based compensation costs of $2.4 million, including $0.1 million recorded to restructuring and related charges. For the three months ended March 31, 2018, we recognized total share-based compensation costs of $1.4 million. We account for forfeitures as they occur. A summary of our stock options as of March 31, 2019 and the changes during the three months then ended is presented below: Options Shares (In thousands) Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term Aggregate Intrinsic Value (In thousands) Outstanding at January 1, 2019 431 $ 17.83 Granted — — Exercised (35 ) 10.70 Forfeited — — Expired — — Outstanding at March 31, 2019 396 $ 18.46 4.4 $ 1,262 Exercisable at March 31, 2019 316 $ 13.57 3.3 $ 1,262 The follow i o w m e i o c a a activit durin th three months then ended: Restricted Stock Awards Shares (In thousands) Weighted- Average Grant Date Fair Value Nonvested at January 1, 2019 — $ — Granted — — Replacement Awards 258 19.42 Vested — — Forfeited — — Nonvested at March 31, 2019 258 $ 19.42 The follow i o w m e i o c a a activit durin th three months then ended: Restricted Stock Units Shares (In thousands) Weighted- Average Grant Date Fair Value Nonvested at January 1, 2019 271 $ 24.07 Granted 141 19.42 Replacement Awards 919 19.42 Vested (68 ) 11.42 Forfeited — — Nonvested at March 31, 2019 1,263 $ 20.84 The follow i o w m a wel a activit durin th three months then ended: Performance Stock Units Shares (In thousands) Weighted- Average Grant Date Fair Value Nonvested at January 1, 2019 — $ — Granted 103 19.42 Vested — Forfeited — Nonvested at March 31, 2019 103 $ 19.42 The follow i o w m a wel a activit durin th three months then ended: Market Stock Units Shares (In thousands) Weighted- Average Grant Date Fair Value Nonvested at January 1, 2019 45 $ 18.25 Granted — — Vested — — Forfeited — — Nonvested at March 31, 2019 45 $ 18.25

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	9. Incom Taxes For the three months ended March 31, 2019 and March 31, 2018, we had an effective income tax rate from continuing operations of 56.0% and 25.1%, respectively. we evaluated the realizability of beginning-of-the-year deferred tax assets and increased the valuation allowance on deferred tax assets related to state net operating loss carryforwards by $1.8 million. In addition, we recorded a $0.9 million reduction in deferred tax assets related to state income tax credits. These adjustments increased our income tax expense for the three months ended by March 31, 2019 by approximately $2.7 million. We file income tax returns in the U.S. Federal jurisdiction and in various state and foreign

Leases

Leases	3 Months Ended
	Mar. 31, 2019
Leases [Abstract]
Leases	10. Leases On January 1, 2019, we adopted ASC 842 using the modified retrospective approach. Therefore, the comparative information for periods ended prior to January 1, 2019 was not restated. Leases with an initial term of 12 months or less are considered short-term and are not recorded on the balance sheet. We recognize lease expense for these short-term leases on a straight-line basis over the lease term. With the exception of one finance lease related to office equipment, all of our leases are classified as operating leases. We maintain lease agreements principally for our office spaces and certain equipment. In addition, certain of our contracts, such as those with our fulfillment vendor related to our warehouse space or contracts with certain equipment vendors, contain embedded leases. We maintain two sublease agreements with respect to one of our office locations, each of which continues through the initial term of our master lease agreement. Such sublease income and payments, while they reduce our rent expense, are not considered in the value of the right-of-use asset or lease liability. In the aggregate, our leases generally have remaining lease terms of one to six years, some of which include options to extend the lease for additional periods. Such extension options were not considered in the value of the right-of-use asset or lease liability since it is not probable that we will exercise the options to extend. If applicable, allocations among lease and nonlease components would be achieved Upon adoption of ASC 842, we determined our estimated discount rate for existing leases as of January 1, 2019 based on the incremental borrowing rate that most closely aligned with the remaining lease term and payment schedule, as provided by our financial institution. The discount rate for leases in the Nutrition segment was estimated as of the Closing date of the Merger. The following table shows the right-of-use assets and lease liabilities recorded on the balance sheet: March 31, 2019 (In thousands) Right-of-use assets: Operating $ 46,578 Finance 169 Total leased assets $ 46,747 Lease liabilities: Current Operating $ 14,762 Finance 46 Non-current Operating $ 35,043 Finance 123 Total lease liabilities $ 49,974 The following table shows the components of lease expense: Three Months Ended March 31, (In thousands) 2019 Finance lease cost: Amortization of leased assets $ 12 Interest of lease liabilities 2 Operating lease cost 2,716 Short-term lease cost 33 Total lease cost before subleases $ 2,763 Sublease income (1,344 ) Total lease cost, net $ 1,419 The following provides information related to the lease term and discount rate as of March 31, 2019: Weighted Average Remaining Lease Term (years) Operating leases 3.6 Finance leases 3.3 Weighted Average Discount Rate Operating leases 5.4 % Finance leases 4.4 % As of March 31, 2019, m aturities of lease liabilities for each of the next five years and thereafter were as follows. Operating Leases Financing (In thousands) Lease Payments Sublease Receipts Net Leases Remaining 2019 $ 12,896 $ (4,233 ) $ 8,663 $ 39 2020 14,828 (5,667 ) 9,161 52 2021 13,361 (5,699 ) 7,662 52 2022 11,339 (5,732 ) 5,607 39 2023 1,947 (956 ) 991 — 2024 and thereafter 379 — 379 — Total lease payments 54,750 $ (22,287 ) $ 32,463 182 Less: interest (4,945 ) (13 ) Present value of lease liabilities $ 49,805 $ 169 Supplemental cash flow information related to leases was as follows: Three Months Ended March 31, (In thousands) 2019 Cash paid for amounts included in the measurement of lease liabilities Operating cash flow attributable to operating leases $ (1,547 ) Operating cash flow attributable to finance leases (2 ) Financing cash flows attributable to finance leases (11 ) Supplemental noncash information: Right-of-use assets obtained in exchange for operating lease liabilities (1) 48,972 Right-of-use assets obtained in exchange for finance lease liabilities (1) 181 (1) No new leases were entered into during the three months ended March 31, 2019. Amounts shown are due to the adoption of ASC 842 and reflect balances as of January 1, 2019 for the Healthcare segment and as of March 8, 2019 for the Nutrition segment (i.e., the date of our acquisition of Nutrisystem). As of December 31, 2018, future minimum lease payments, net of total cash receipts from subleases of $23.7 million, under all non-cancelable operating leases for each of the next five years and thereafter were as follows. As of December 31, 2018, future minimum lease payments under capital leases were not material. (In thousands) Operating Year ending December 31, Leases 2019 $ 4,022 2020 2,040 2021 910 2022 827 2023 136 2024 and thereafter — Total minimum lease payments $ 7,935

Debt

Debt	3 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
Debt	11. De b The C o an o i n (In thousands) March 31, 2019 December 31, 2018 Term Loan A $ 341,000 $ — Term Loan B 824,000 — Delayed draw term loan — 25,000 Revolving credit facility — 5,450 Capital lease obligations and other (1) — 196 1,165,000 30,646 Less: deferred loan costs and original issue discount ("OID") (53,160 ) — 1,111,840 30,646 Less: current portion (44,900 ) (57 ) $ 1,066,940 $ 30,589 (1) Prior to the adoption of ASC 842 on January 1, 2019, our capital leases were recorded as part of debt. Beginning on January 1, 2019, they are classified as financing leases under ASC 842 and are recorded as part of lease liabilities. Credit Facility In connection with the consummation of the Merger, on March 8, 2019, we entered into a new Credit and Guaranty Agreement (the “Credit Agreement”) with a group of lenders, Credit Suisse AG, Cayman Islands Branch, as general administrative agent, term facility agent and collateral agent, and SunTrust Bank, as revolving facility agent and swing line lender (“SunTrust”). The Credit Agreement replaced our prior Revolving Credit and Term Loan Agreement, dated April 21, 2017 (the “Prior Credit Agreement”), with a group of lenders and SunTrust, as administrative agent. The Credit Agreement provides us with (i) a $350.0 million term loan A facility (“Term Loan A”), (ii) an $830.0 million term loan B facility (“Term Loan B” and, together with Term Loan A, the “Term Loans”), (iii) a $125.0 million revolving credit facility that includes a $35.0 million sublimit for swingline loans and a $50.0 million sublimit for letters of credit (the “Revolving Credit Facility”; Term Loan A, Term Loan B and the Revolving Credit Facility are sometimes herein referred to collectively as the “Credit Facilities”), and (iv) uncommitted incremental accordion facilities in an aggregate amount at any date equal to the greater of $125.0 million or 50% of our consolidated EBITDA for the then-preceding four fiscal quarters, plus additional amounts based on, among other things, satisfaction of certain financial ratio requirements. We used the proceeds of the Term Loans, borrowings under the Revolving Credit Facility and cash on hand to pay the Merger Consideration, to repay all of the outstanding indebtedness under the Prior Credit Agreement and all outstanding indebtedness of Nutrisystem under its credit agreement, and to pay transaction costs and expenses. Proceeds of the Revolving Credit Facility also may be used for general corporate purposes of the Company and its subsidiaries. We are required to repay Term Loan A loans in consecutive quarterly installments, each in the amount of 2.50% of the aggregate initial amount of such loans, payable on June 30, 2019 and on the last day of each succeeding quarter thereafter until maturity on March 8, 2024, at which time the entire outstanding principal balance of such loans is due and payable in full. We are required to repay Term Loan B loans in consecutive quarterly installments, each in the amount of 0.75% of the aggregate initial amount of such loans, payable on June 30, 2019 and on the last day of each succeeding quarter thereafter until maturity on March 8, 2026, at which time the entire outstanding principal balance of such loans is due and payable in full. We are permitted to make voluntarily prepayments of borrowings under the Term Loans at any time without penalty. We are required to repay in full any outstanding swingline loans and revolving loans under the Revolving Credit Facility on March 8, 2024. Borrowings under the Credit Agreement bear interest at variable rates based on a margin or spread in excess of either (1) one-month, two-month, three-month or six-month LIBOR (or, with the approval of all lenders holding the particular class of loans, 12-month LIBOR), which may not be less than zero, or (2) the greatest of (a) the prime lending rate of the agent bank for the particular facility, (b) the federal funds rate plus 0.50%, and (c) one-month LIBOR plus 1.00% (the “Base Rate”), as selected by the Company. The LIBOR margin for Term Loan A loans is 4.25%, the LIBOR margin for Term Loan B loans is 5.25% and the LIBOR margin for revolving loans varies between 3.75% and 4.25%, depending on our total net leverage ratio. The Base Rate margin for Term Loan A loans is 3.25%, the Base Rate margin for Term Loan B loans is 4.25% and the Base Rate margin for revolving loans varies between 2.75% and 3.25%, depending on our total net leverage ratio. The Credit Agreement also provides for annual commitment fees ranging between 0.250% and 0.500% of the unused commitments under the Revolving Credit Facility, depending on our total net leverage ratio, and annual letter of credit fees on the daily outstanding availability under outstanding letters of credit at the applicable LIBOR margin for the Revolving Credit Facility, depending on our total net leverage ratio. The Credit Agreement contains a financial covenant that requires us to maintain specified maximum ratios or levels of consolidated total net debt to EBITDA, calculated as provided in the Credit Agreement. The Credit Agreement also contains various other affirmative and negative covenants customary for financings of this type that, subject to certain exceptions, impose restrictions and limitations on the Company and certain of the Company’s subsidiaries with respect to, among other things, indebtedness; liens; negative pledges; restricted payments (including dividends, distributions, buybacks, redemptions, repurchases with respect to equity interests, and payments, redemptions, retirements, purchases, acquisitions, defeasance, exchange, conversion, cancellation or termination with respect to junior lien, subordinated or unsecured debt); restrictions on subsidiary distributions; loans, advances, guarantees, acquisitions and other investments; mergers and other fundamental changes; sales and other dispositions of assets (including equity interests in subsidiaries); sale/leaseback transactions; transactions with affiliates; conduct of business; amendments and waivers of organizational documents and material junior debt agreements; and changes to fiscal year. Warrants In July 2013, we sold separate privately negotiated warrants (the “Warrants”) initially relating, in the aggregate, to approximately 7.7 million shares of our Common Stock. The Warrants are call options with an initial strike price of approximately $25.95 per share. Since October 1, 2018, the Warrants have been subject to automatic exercise on a pro rata basis each trading day continuing for a period of 160 trading days (i.e., approximately 48,000 warrants are subject to automatic exercise on each trading day). The Warrants are net share settled by our issuing a number of shares of our Common Stock per Warrant with a value corresponding to the excess of the market price per share of our Common Stock (as measured on each warrant exercise date under the terms of the Warrants) over the applicable strike price of the Warrants. If such market price per share is less than the applicable strike price of the Warrants on any given exercise date, then the warrants subject to automatic exercise on such exercise date are not exercised but instead expire. The Warrants meet the definition of derivatives under the guidance in ASC Topic 815; however, because these instruments have been determined to be indexed to our own stock and meet the criteria for equity classification under ASC Topic 815, the Warrants have been accounted for as an adjustment to our additional paid-in-capital. During the three months ended March 31, 2019, we did not issue any shares of Common Stock related to the automatic exercise of the Warrants due to the market price per share of our Common Stock being less than the applicable strike price of the Warrants on each exercise date during such time period. When the market price per share of our Common Stock exceeds the strike price of the Warrants, the Warrants have a dilutive effect on net income per share, and the “treasury stock” method is used in calculating the dilutive effect on earnings per share. See Note 15 for additional information on such dilutive effect.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2019
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	12. Commitment an Contingencies Weiner, Denham, Allen, and Witmer Lawsuits On November 6, 2017, United Healthcare issued a press release announcing expansion of its fitness benefits (“United Press Release”), and the market price of the Company's shares of Common Stock dropped on that same day. In connection with the United Press Release, four lawsuits have been filed against the Company as described below. We are currently not able to predict the probable outcome of these matters or to reasonably estimate a range of potential losses, if any. We intend to vigorously defend ourselves against all four complaints. On November 20, 2017, Eric Weiner, claiming to be a stockholder of the Company, filed a complaint on behalf of stockholders who purchased the Company’s Common Stock between February 24, 2017 and November 3, 2017 (“Weiner Lawsuit”). The Weiner Lawsuit was filed as a class action in the U.S. District Court for the Middle District of Tennessee, naming as defendants the Company, the Company's chief executive officer, chief financial officer and a former executive who served as both chief accounting officer and interim chief financial officer. The complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated under the Exchange Act in making false and misleading statements and omissions related to the United Press Release. The complaint seeks monetary damages on behalf of the purported class. On April 3, 2018, the Court entered an order appointing the Oklahoma Firefighters Pension and Retirement System as lead plaintiff, designated counsel for the lead plaintiff, and established certain deadlines for the case. On June 4, 2018, plaintiff filed a first amended complaint. On August 3, 2018, the Company filed a motion to dismiss the first amended complaint and a memorandum in support of a motion to dismiss seeking dismissal on grounds that the first amended complaint fails to plead any actionable statement or omission (the “Motion to Dismiss”) . On January 26, 2018, Charles Denham, claiming to be a stockholder of the Company, filed a purported shareholder derivative action, on behalf of the Company, in the U.S. District Court for the Middle District of Tennessee, naming the Company as a nominal defendant and the Company's chief executive officer, chief financial officer, a former executive who served as both chief accounting officer and interim chief financial officer, current directors and a former director of the Company, as defendants (“Denham Lawsuit”). The complaint asserts claims for breach of fiduciary duty, waste, and unjust enrichment, largely tracking allegations in the Weiner Lawsuit. The complaint further alleges that certain defendants engaged in insider trading. The plaintiff seeks monetary damages on behalf of the Company, certain corporate governance and internal procedural reforms, and other equitable relief On August 24, 2018, Andrew H. Allen, claiming to be a stockholder of the Company, filed a purported shareholder derivative action, on behalf of the Company, in the U.S. District Court for the Middle District of Tennessee, naming the Company as a nominal defendant and the Company’s chief executive officer, chief financial officer, a former executive who served as both chief accounting officer and interim chief financial officer, together with nine current or former directors, as defendants (the “Allen Lawsuit”). The complaint asserts claims for breach of fiduciary duty and violations of the Securities Act of 1933, as amended (the “Securities Act”) and the Exchange Act against all individual defendants, largely tracking allegations in the Weiner Lawsuit and Denham Lawsuit, and breach of fiduciary duty for insider trading against a former executive who served as both chief accounting officer and interim chief financial officer and one of the directors of the Company. The plaintiff seeks to recover damages on behalf of the Company, certain corporate governance and internal procedural reforms, and other equitable relief, including restitution from the two defendants alleged to have engaged in insider trading from all unlawfully obtained profits. On October 15, 2018, the Allen Lawsuit and the Denham Lawsuit were consolidated by stipulation. On March 25, 2019, Colleen Witmer, claiming to be a stockholder of the Company, filed a purported shareholder derivative action, on behalf of the Company, in the Chancery Court for Davidson County, Tennessee, naming the Company as a nominal defendant and the Company's chief executive officer, chief financial officer, a former executive who served as both chief accounting officer and interim chief financial officer, chief legal and administrative officer, certain current directors, and two former directors of the Company, as defendants. The complaint asserts claims for breach of fiduciary duty and unjust enrichment, largely tracking allegations in the Denham Lawsuit. The complaint further alleges that certain defendants engaged in insider trading. The plaintiff seeks monetary damages on behalf of the Company, restitution, certain corporate governance and internal procedural reforms, and other equitable relief. Other Additionally, from time to time, we are subject to contractual disputes, claims and legal proceedings that arise in the ordinary course of our business. Some of the legal proceedings pending against us as of the date of this report are expected to be covered by insurance policies. As these matters are subject to inherent uncertainties, our view of these matters may change in the future. We expense legal costs as incurred.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements	13. Fai Valu Measu r ments We account for certain assets and liabilities at fair value. Fair value is defined as the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date, assuming the transaction occurs in the principal or most advantageous market for that asset or liability. Fair Value Hierarchy The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. We categorize each of our fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are: Level 1: Quoted prices in active markets for identical assets or liabilities; Level 2: Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-based valuation techniques in which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and Level 3: Unobservable inputs that are supported by little or no market activity and typically reflect management's estimates of assumptions that market participants would use in pricing the asset or liability. Asse t i e i e n i There were no assets and liabilities u i a Fair Value of Other Financial Instruments The e a n n m a o C a a e y r e o n um e s a o D e i a a b o i u e h A e m u e e e is det e m ine b a s e o th fai val u hierarch a disc u sse a bove T he Term Loans are e o l i a e the last quoted price of the Term Loans through March 31, 2019 Th e volvin redi acilit The estimated fair value and carrying amount of outstanding borrowings under the Term Loans at March 31, 2019 were $1,146 million and $1,165 million, respectively.

Restructuring and Related charg

Restructuring and Related charges	3 Months Ended
	Mar. 31, 2019
Restructuring And Related Activities [Abstract]
Restructuring and Related Charges	14. Restructuring and Related Charges During the first quarter of 2019, we began a reorganization primarily related to integrating the Healthcare and Nutrition segments and streamlining our corporate and operations support (the "2019 Restructuring Plan"). To date, we have incurred restructuring charges of $1.6 million related to actions executed in the first quarter of 2019 (the “Q1 2019 Actions”), of which $1.0 million related to the Healthcare segment and $0.6 million related to the Nutrition segment. These expenses consist entirely of severance and other employee-related costs. The Q1 2019 Actions are expected to result in additional costs of $0.8 million during the second quarter of 2019, all of which relates to the Nutrition segment. Although we expect further actions to be taken under the 2019 Restructuring Plan during the remainder of 2019 that will result in additional restructuring charges and future savings, the Q1 2019 Actions are expected to result in total annualized savings of approximately $7.2 million, with $3.5 million relating to the Healthcare segment and $3.7 million relating to the Nutrition segment.

Earnings Per Share

Earnings Per Share	3 Months Ended
	Mar. 31, 2019
Earnings Per Share [Abstract]
Earnings Per Share	1 5 . Earning Pe Sha r The i e o a u o n i o i d g e o n (In thousands except per share data) Three March 31, 2019 2018 Numerator: Net income $ 4,214 $ 21,336 Denominator: Shares used for basic income per share 42,745 39,783 Effect of dilutive stock options and restricted stock units outstanding: Non-qualified stock options 127 312 Restricted stock awards 16 — Restricted stock units 292 405 Performance stock units 3 — Market stock units — 533 Warrants related to Cash Convertible Notes — 2,556 Shares used for diluted income per share 43,183 43,589 Earnings per share: Basic $ 0.10 $ 0.54 Diluted $ 0.10 $ 0.49 Dilutive securities outstanding not included in the computation of earnings per share because their effect is anti-dilutive: Non-qualified stock options 80 — Restricted stock units 56 14 (1) Figures may not add due to rounding. Market stock units outstanding are considered contingently issuable shares, and certain of these stock units were excluded from the calculations of diluted earnings per share for all periods presented as the performance criteria had not been met as of the end of the reporting periods.

Segment Information

Segment Information	3 Months Ended
	Mar. 31, 2019
Segment Reporting [Abstract]
Segment Information	16. Segment Information Following the acquisition of Nutrisystem in March 2019, we organize and manage our operations within two reportable segments, based on the types of products and services they offer: Healthcare and Nutrition. The Healthcare segment consists of Each segment’s profit is measured as earnings before interest, taxes, depreciation and amortization (“EBITDA”) excluding acquisition and integration costs and restructuring and related charges, as shown below: (In thousands) Three Months Ended March 31, 2019 Healthcare Nutrition Consolidated Revenues $ 156,527 $ 57,567 $ 214,094 Adjusted EBITDA $ 26,129 $ 13,344 $ 39,473 Acquisition and integration costs $ 17,052 Restructuring and related charges 1,591 Interest expense 7,666 Depreciation and amortization 3,582 Income before income taxes $ 9,582 Total assets as of March 31, 2019 $ 456,017 $ 1,614,571 $ 2,070,588

Basis of Presentation (Policies

Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Basis of Presentation	Our financial statements and accompanying notes are prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”). In our opinion, the accompanying consolidated financial statements of Tivity Health ® ® We have reclassified certain items in prior periods to conform to current classifications. Following the acquisition of Nutrisystem, we organize and manage our operations within two reportable segments, based on the types of products and services they offer: Healthcare and Nutrition. The Healthcare segment is comprised of our legacy business and includes SilverSneakers senior fitness, Prime Fitness and WholeHealth Living TM ® and the South Beach Diet ® products. We have omitted certain financial information that is normally included in financial statements prepared in accordance with U.S. GAAP but that is not required for interim reporting purposes. You should read the accompanying consolidated financial statements in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2018.
Recent Relevant Accounting Standards	On January 1, 2019, we adopted Accounting Standards Update (“ASU”) We elected to recognize the cumulative effect of initially applying the standard as an adjustment to beginning retained earnings as of January 1, 2019. The significant majority of our leases are classified as operating leases. As of January 1, 2019, we recognized a right-of-use asset of $27.0 million and lease liabilities of $29.7 million. On March 8, 2019, we assumed existing leases from Nutrisystem and recognized additional right-of-use assets and lease liabilities of $22.1 million each. In addition, we elected the following practical expedients available under ASC 842: (1) the package of practical expedients whereby we are not required to reassess upon adoption of ASC 842 (a) whether a contract is or contains a lease, (b) lease classification, and (c) initial direct costs (ASC 842-10-65-1(f)); and (2) the short-term lease measurement and recognition exemption (ASC 842-20-25-2). ASC 842 also requires significant new disclosures about leasing activity In January 2017, the FASB issued ASU No. 2017-04, “Intangibles - Goodwill and Other” (“ASU 2017-04”), which simplifies the subsequent measurement of goodwill by eliminating step two from the goodwill impairment test. ASU 2017-04 is effective for annual and interim impairment tests in fiscal years beginning after December 15, 2019 and is required to be applied prospectively. Early adoption is allowed for annual goodwill impairment tests performed on testing dates after January 1, 2017. We do not anticipate that adopting this standard will have an impact on our consolidated financial statements and related disclosures. In August 2018, the FASB issued ASU No. 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement” (“ASU 2018-13”), which changes the fair value measurement disclosure requirements of ASC 820. ASU 2018-13 is effective for fiscal years beginning on or after December 15, 2019, including interim periods therein, and is generally required to be applied retrospectively, except for certain components that are to be applied prospectively. Early adoption is permitted for any eliminated or modified disclosures. We do not anticipate that adopting this standard will have a material impact on our disclosures. In August 2018, the FASB issued ASU No. 2018-15, “Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract,” which requires implementation costs incurred by customers in cloud computing arrangements to be deferred and recognized over the term of the arrangement, if those costs would be capitalized by the customer in a software licensing arrangement. This standard is effective for annual periods beginning after December 15, 2019, and interim periods within those fiscal years. We do not anticipate that adopting this standard will have a material impact on our consolidated financial statements and related disclosures. In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”), which requires companies to measure credit losses for financial assets held at the reporting date utilizing a methodology that reflects current expected credit losses over the lifetime of such assets. ASU 2016-13 is effective for the Company on January 1, 2020 and is generally required to be applied using the modified retrospective approach, with limited exceptions for specific instruments. We do not anticipate that adopting this standard will have an impact on our consolidated financial statements and related disclosures.

Business Combinations (Tables)

Business Combinations (Tables)	3 Months Ended
	Mar. 31, 2019
Business Combinations [Abstract]
Summary of Component of Merger Consideration	The following table summarizes the components of the Merger Consideration: (In thousands) Cash paid for outstanding Nutrisystem shares (1) $ 1,138,143 Value of Tivity Health Common Stock issued in the merger (2) 132,838 Value of Nutrisystem stock options (3) 6,020 Value of Tivity Health replacement awards attributable to pre-combination service (4) 9,107 Total Merger Consideration $ 1,286,108 (1) Represents the total cash paid to former Nutrisystem stockholders as cash consideration. This amount is based on the 29,370,594 shares of Nutrisystem common stock issued and outstanding as of Closing and cash consideration of $38.75 per share, plus cash payable in lieu of fractional shares. (2) Represents the fair value of 6.3 million shares of Tivity Health Common Stock issued for outstanding Nutrisystem shares as stock consideration. This amount is based on (a) 29,370,594 Nutrisystem common shares issued and outstanding as of Closing, times (b) the Exchange Ratio of 0.2141, times (c) $21.12, which is equal to the volume-weighted averages of the trading price per share of our Common Stock for the five consecutive trading days up to and including March 6, 2019. (3) Represents the fair value of the cash consideration paid for the net settlement of approximately 204,000 Nutrisystem stock options vested and outstanding as of the closing date. In accordance with the Merger Agreement, each vested and outstanding Nutrisystem stock option was cancelled, and the holder received a cash payment per option equal to approximately $43.27 minus the applicable exercise price of the stock option. (4) U nvested restricted stock awards and performance stock units held by Nutrisystem employees were assumed by Tivity Health and converted into time-vesting restricted stock awards and time-vesting restricted stock units, respectively (“Replacement Awards”). The value in the table represents the portion of the fair value of the Replacement Awards that relates to pre-combination services.
Preliminary Allocation of Estimated Merger Consideration to the Identifiable Tangible and Intangible Assets Acquired and Liabilities Assumed	We performed a valuation analysis of the fair market value of Nutrisystem’s assets and liabilities as of Closing. The following table sets forth an allocation of the Merger Consideration to the identifiable tangible and intangible assets acquired and liabilities assumed, with the excess recorded to goodwill. This allocation of the Merger Consideration may be subject to revision if new facts and circumstances arise over the measurement period, which may extend up to one year from Closing. (In thousands) Cash, cash equivalents, and short-term investments $ 81,217 Accounts receivable 22,639 Inventory 38,494 Prepaid expenses and other current assets 12,345 Property and equipment 31,233 Right-of-use assets 22,145 Intangible assets 948,000 Other assets/liabilities 7,161 Accounts payable (58,253 ) Accrued salaries and benefits and other liabilities (8,695 ) Deferred revenue (13,339 ) Lease liabilities (22,145 ) Deferred tax liabilities, net (220,365 ) Total identifiable assets and liabilities acquired $ 840,437 Goodwill (1) 445,671 Total Merger Consideration $ 1,286,108 (1) Goodwill represents the excess of merger consideration over the preliminary fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Nutrisystem and synergies expected to be achieved from the combined operations of Tivity Health and Nutrisystem.
Summary of Pro forma Combined Company Results	The following financial information presents the pro forma combined company results as if the acquisition of Nutrisystem had occurred on January 1, 2018: (In thousands) Three Months Ended March 31, 2019 2018 Revenue $ 347,542 $ 360,860 Net loss $ (4,635 ) $ (29,842 )

Revenue Recognition (Tables)

Revenue Recognition (Tables)	3 Months Ended
	Mar. 31, 2019
Summary of Information about Contract Assets and Contract Liabilities from Contracts with Customers	The following table provides information about receivables, contract assets and contract liabilities from contracts with customers: (In thousands) March 31, 2019 Contract assets $ 480 Contract liabilities $ 14,997 Significant changes in the contract liabilities (deferred revenue) balance during the period are as follows: Three Months Ended March 31, (In thousands) 2019 Revenue recognized that was included in the contract liability (deferred revenue) balance on March 8, 2019 $ (2,752 ) Increases due to cash received for prepaid gift cards sold or unshipped food, excluding amounts recognized as revenue $ 4,409
Summary of Revenue from Prepaid Gift Cards Expected to be Recognized in Future Related to Performance Obligation Unsatisfied or Partially Satisfied	The following table includes estimated revenue from the prepaid gift cards expected to be recognized in the future related to performance obligations that are unsatisfied (or partially satisfied) at the end of the reporting period: (In thousands) Remaining 2019 $ 10,665 2020 1,303 2021 665 $ 12,633
Healthcare
Summary of Revenue Disaggregated	The following table sets forth Healthcare revenue disaggregated by program. Revenue from our SilverSneakers program is predominantly contracted with Medicare Advantage and Medicare Supplement plans. (In thousands) Three Months Ended March 31, 2019 2018 SilverSneakers $ 123,024 $ 120,925 Prime Fitness 28,743 24,734 WholeHealth Living 4,575 4,217 Other 185 54 $ 156,527 $ 149,930
Nutrition
Summary of Revenue Disaggregated	The following table sets forth Nutrition segment revenue disaggregated by the source of revenue: (In thousands) Three Months Ended March 31, 2019 Direct to consumer $ 52,654 Retail 4,304 QVC 522 Other 87 $ 57,567

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	3 Months Ended
	Mar. 31, 2019
Goodwill And Intangible Assets Disclosure [Abstract]
Intangible Assets Subject to and Not Subject to Amortization	(In thousands) Fair Value Estimated Useful Life (in years) Intangible assets subject to amortization: Tradename - South Beach Diet 9,000 15 Customer list 125,000 7 Retail customer relationship 8,000 10 Noncompetition agreements 6,000 5 Subtotal $ 148,000 Intangible assets not subject to amortization: Tradename - Nutrisystem 800,000 n/a Total intangible assets $ 948,000 Goodwill 445,671 n/a
Change in Carrying Amount of Goodwill	The change in the carrying amount of goodwill during the three months ended March 31, 2019 was as follows: (In thousands) Balance, January 1, 2019 $ 334,680 Acquisition of Nutrisystem 445,671 Balance, March 31, 2019 $ 780,351

Share-Based Compensation (Table

Share-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Stock Options	A summary of our stock options as of March 31, 2019 and the changes during the three months then ended is presented below: Options Shares (In thousands) Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term Aggregate Intrinsic Value (In thousands) Outstanding at January 1, 2019 431 $ 17.83 Granted — — Exercised (35 ) 10.70 Forfeited — — Expired — — Outstanding at March 31, 2019 396 $ 18.46 4.4 $ 1,262 Exercisable at March 31, 2019 316 $ 13.57 3.3 $ 1,262
Summary of Restricted Stock Awards	The follow i o w m e i o c a a activit durin th three months then ended: Restricted Stock Awards Shares (In thousands) Weighted- Average Grant Date Fair Value Nonvested at January 1, 2019 — $ — Granted — — Replacement Awards 258 19.42 Vested — — Forfeited — — Nonvested at March 31, 2019 258 $ 19.42
Summary of Restricted Stock Units	The follow i o w m e i o c a a activit durin th three months then ended: Restricted Stock Units Shares (In thousands) Weighted- Average Grant Date Fair Value Nonvested at January 1, 2019 271 $ 24.07 Granted 141 19.42 Replacement Awards 919 19.42 Vested (68 ) 11.42 Forfeited — — Nonvested at March 31, 2019 1,263 $ 20.84
Summary of Performance Stock Units	The follow i o w m a wel a activit durin th three months then ended: Performance Stock Units Shares (In thousands) Weighted- Average Grant Date Fair Value Nonvested at January 1, 2019 — $ — Granted 103 19.42 Vested — Forfeited — Nonvested at March 31, 2019 103 $ 19.42
Summary of Market Stock Units	The follow i o w m a wel a activit durin th three months then ended: Market Stock Units Shares (In thousands) Weighted- Average Grant Date Fair Value Nonvested at January 1, 2019 45 $ 18.25 Granted — — Vested — — Forfeited — — Nonvested at March 31, 2019 45 $ 18.25

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2019
Leases [Abstract]
Schedule of Right-of-Use Assets and Lease Liabilities	The following table shows the right-of-use assets and lease liabilities recorded on the balance sheet: March 31, 2019 (In thousands) Right-of-use assets: Operating $ 46,578 Finance 169 Total leased assets $ 46,747 Lease liabilities: Current Operating $ 14,762 Finance 46 Non-current Operating $ 35,043 Finance 123 Total lease liabilities $ 49,974
Schedule of Components of Lease Expense	The following table shows the components of lease expense: Three Months Ended March 31, (In thousands) 2019 Finance lease cost: Amortization of leased assets $ 12 Interest of lease liabilities 2 Operating lease cost 2,716 Short-term lease cost 33 Total lease cost before subleases $ 2,763 Sublease income (1,344 ) Total lease cost, net $ 1,419
Schedule of Weighted Average Remaining Term and Discount Rates	The following provides information related to the lease term and discount rate as of March 31, 2019: Weighted Average Remaining Lease Term (years) Operating leases 3.6 Finance leases 3.3 Weighted Average Discount Rate Operating leases 5.4 % Finance leases 4.4 %
Schedule of Maturities of Lease Liabilities	As of March 31, 2019, m aturities of lease liabilities for each of the next five years and thereafter were as follows. Operating Leases Financing (In thousands) Lease Payments Sublease Receipts Net Leases Remaining 2019 $ 12,896 $ (4,233 ) $ 8,663 $ 39 2020 14,828 (5,667 ) 9,161 52 2021 13,361 (5,699 ) 7,662 52 2022 11,339 (5,732 ) 5,607 39 2023 1,947 (956 ) 991 — 2024 and thereafter 379 — 379 — Total lease payments 54,750 $ (22,287 ) $ 32,463 182 Less: interest (4,945 ) (13 ) Present value of lease liabilities $ 49,805 $ 169
Schedule of Supplemental Cash Flow Information Related to Leases	Supplemental cash flow information related to leases was as follows: Three Months Ended March 31, (In thousands) 2019 Cash paid for amounts included in the measurement of lease liabilities Operating cash flow attributable to operating leases $ (1,547 ) Operating cash flow attributable to finance leases (2 ) Financing cash flows attributable to finance leases (11 ) Supplemental noncash information: Right-of-use assets obtained in exchange for operating lease liabilities (1) 48,972 Right-of-use assets obtained in exchange for finance lease liabilities (1) 181 (1) No new leases were entered into during the three months ended March 31, 2019. Amounts shown are due to the adoption of ASC 842 and reflect balances as of January 1, 2019 for the Healthcare segment and as of March 8, 2019 for the Nutrition segment (i.e., the date of our acquisition of Nutrisystem).
Summary of Future Minimum Lease Payments Under All Non-cancelable Operating Leases	As of December 31, 2018, future minimum lease payments, net of total cash receipts from subleases of $23.7 million, under all non-cancelable operating leases for each of the next five years and thereafter were as follows. As of December 31, 2018, future minimum lease payments under capital leases were not material. (In thousands) Operating Year ending December 31, Leases 2019 $ 4,022 2020 2,040 2021 910 2022 827 2023 136 2024 and thereafter — Total minimum lease payments $ 7,935

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
Summary of Debt, Net of Unamortized Deferred Loan Costs And Original Issue Discount	The C o an o i n (In thousands) March 31, 2019 December 31, 2018 Term Loan A $ 341,000 $ — Term Loan B 824,000 — Delayed draw term loan — 25,000 Revolving credit facility — 5,450 Capital lease obligations and other (1) — 196 1,165,000 30,646 Less: deferred loan costs and original issue discount ("OID") (53,160 ) — 1,111,840 30,646 Less: current portion (44,900 ) (57 ) $ 1,066,940 $ 30,589 (1) Prior to the adoption of ASC 842 on January 1, 2019, our capital leases were recorded as part of debt. Beginning on January 1, 2019, they are classified as financing leases under ASC 842 and are recorded as part of lease liabilities.

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Mar. 31, 2019
Earnings Per Share [Abstract]
Reconciliation of the Numerator and Denominator of Basic and Diluted Earnings Per Share	The i e o a u o n i o i d g e o n (In thousands except per share data) Three March 31, 2019 2018 Numerator: Net income $ 4,214 $ 21,336 Denominator: Shares used for basic income per share 42,745 39,783 Effect of dilutive stock options and restricted stock units outstanding: Non-qualified stock options 127 312 Restricted stock awards 16 — Restricted stock units 292 405 Performance stock units 3 — Market stock units — 533 Warrants related to Cash Convertible Notes — 2,556 Shares used for diluted income per share 43,183 43,589 Earnings per share: Basic $ 0.10 $ 0.54 Diluted $ 0.10 $ 0.49 Dilutive securities outstanding not included in the computation of earnings per share because their effect is anti-dilutive: Non-qualified stock options 80 — Restricted stock units 56 14 (1) Figures may not add due to rounding.

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Mar. 31, 2019
Segment Reporting [Abstract]
Schedule of Each Segment's Profit	Each segment’s profit is measured as earnings before interest, taxes, depreciation and amortization (“EBITDA”) excluding acquisition and integration costs and restructuring and related charges, as shown below: (In thousands) Three Months Ended March 31, 2019 Healthcare Nutrition Consolidated Revenues $ 156,527 $ 57,567 $ 214,094 Adjusted EBITDA $ 26,129 $ 13,344 $ 39,473 Acquisition and integration costs $ 17,052 Restructuring and related charges 1,591 Interest expense 7,666 Depreciation and amortization 3,582 Income before income taxes $ 9,582 Total assets as of March 31, 2019 $ 456,017 $ 1,614,571 $ 2,070,588

Basis of Presentation - Additio

Basis of Presentation - Additional Information (Details)	3 Months Ended
	Mar. 31, 2019Segment
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Number of reportable segments	2

Business Combinations - Additio

Business Combinations - Additional Information (Details) $ / shares in Units, $ in Thousands	Mar. 08, 2019USD ($)$ / shares	Dec. 09, 2018	Mar. 31, 2019USD ($)	Mar. 31, 2018USD ($)
Business Acquisition [Line Items]
Increase (decrease) in acquisition, integration, and restructuring costs			$ (33,400)	$ 38,700
Increase (decrease) in income tax expense			$ (2,700)	2,700
Increase in cost of revenue				$ 2,800
Nutrisystem, Inc.
Business Acquisition [Line Items]
Business acquisition, cash received in conversion | $ / shares	$ 38.75
Business acquisition, common stock exchange ratio	0.2141
Merger consideration	$ 1,286,108
Nutrisystem, Inc. | Merger Agreement
Business Acquisition [Line Items]
Business acquisition, agreement date		Dec. 9, 2018
Business acquisition, effective date of acquisition	Mar. 8, 2019
Business acquisition, cash received in conversion | $ / shares	$ 38.75
Business acquisition, common stock exchange ratio	0.2141

Business Combinations - Summary

Business Combinations - Summary of Component of Merger Consideration (Details) - Nutrisystem, Inc. $ in Thousands	Mar. 08, 2019USD ($)
Business Acquisition [Line Items]
Cash paid for outstanding Nutrisystem shares	$ 1,138,143	[1]
Value of Tivity Health Common Stock issued in the merger	132,838	[2]
Value of Nutrisystem stock options	6,020	[3]
Value of Tivity Health replacement awards attributable to pre-combination service	9,107	[4]
Total Merger Consideration	$ 1,286,108
[1]	Represents the total cash paid to former Nutrisystem stockholders as cash consideration. This amount is based on the 29,370,594 shares of Nutrisystem common stock issued and outstanding as of Closing and cash consideration of $38.75 per share, plus cash payable in lieu of fractional shares.
[2]	Represents the fair value of 6.3 million shares of Tivity Health Common Stock issued for outstanding Nutrisystem shares as stock consideration. This amount is based on (a) 29,370,594 Nutrisystem common shares issued and outstanding as of Closing, times (b) the Exchange Ratio of 0.2141, times (c) $21.12, which is equal to the volume-weighted averages of the trading price per share of our Common Stock for the five consecutive trading days up to and including March 6, 2019.
[3]	Represents the fair value of the cash consideration paid for the net settlement of approximately 204,000 Nutrisystem stock options vested and outstanding as of the closing date. In accordance with the Merger Agreement, each vested and outstanding Nutrisystem stock option was cancelled, and the holder received a cash payment per option equal to approximately $43.27 minus the applicable exercise price of the stock option.
[4]	Unvested restricted stock awards and performance stock units held by Nutrisystem employees were assumed by Tivity Health and converted into time-vesting restricted stock awards and time-vesting restricted stock units, respectively (“Replacement Awards”). The value in the table represents the portion of the fair value of the Replacement Awards that relates to pre-combination services.

Business Combinations - Summa_2

Business Combinations - Summary of Component of Merger Consideration (Parenthetical) (Details) - Nutrisystem, Inc.	Mar. 08, 2019$ / sharesshares
Business Acquisition [Line Items]
Number of Shares converted into cash upon acquisition | shares	29,370,594
Cash consideration per share | $ / shares	$ 38.75
Business acquisition, share issued in conversion | shares	6,300,000
Business acquisition, common stock exchange ratio	0.2141
Volume-weighted average of trading price of common stock | $ / shares	$ 21.12
Number of consecutive trading days	5 days
Stock options vested and outstanding | shares	204,000
Business acquisition cash payment per option net of exercise price | $ / shares	$ 43.27

Business Combinations - Prelimi

Business Combinations - Preliminary Allocation of Estimated Merger Consideration to the Identifiable Tangible and Intangible Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Mar. 08, 2019		Dec. 31, 2018
Business Acquisition [Line Items]
Goodwill, net	$ 780,351			$ 334,680
Nutrisystem, Inc.
Business Acquisition [Line Items]
Cash, cash equivalents, and short-term investments		$ 81,217
Accounts receivable		22,639
Inventory		38,494
Prepaid expenses and other current assets		12,345
Property and equipment		31,233
Right-of-use assets		22,145
Intangible assets		948,000
Other assets/liabilities		7,161
Accounts payable		(58,253)
Accrued salaries and benefits and other liabilities		(8,695)
Deferred revenue		(13,339)
Lease liabilities		(22,145)
Deferred tax liabilities, net		(220,365)
Total identifiable assets and liabilities acquired		840,437
Goodwill, net	$ 445,671	445,671	[1]
Total Merger Consideration		$ 1,286,108
[1]	Goodwill represents the excess of merger consideration over the preliminary fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Nutrisystem and synergies expected to be achieved from the combined operations of Tivity Health and Nutrisystem.

Business Combinations - Summa_3

Business Combinations - Summary of Pro forma Combined Company Results (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Business Combinations [Abstract]
Revenue	$ 347,542	$ 360,860
Net loss	$ (4,635)	$ (29,842)

Recent Relevant Accounting St_2

Recent Relevant Accounting Standards - Additional Information (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Mar. 08, 2019	Jan. 01, 2019
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Right-of-use asset	$ 46,747
Lease liabilities	$ 49,974
ASU 2016-02
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Right-of-use asset			$ 27,000
Lease liabilities			$ 29,700
ASU 2016-02 | Nutrisystem, Inc.
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Right-of-use asset		$ 22,100
Lease liabilities		$ 22,100

Revenue Recognition - Additiona

Revenue Recognition - Additional Information (Details)	3 Months Ended
	Mar. 31, 2019USD ($)SegmentProgramObligationSource	Mar. 31, 2018USD ($)
Disaggregation Of Revenue [Line Items]
Number of reportable segments | Segment	2
Revenue, Practical Expedient, Initial Application and Transition, Qualitative Assessment	true
Revenues	$ 214,094,000	$ 149,930,000
Healthcare
Disaggregation Of Revenue [Line Items]
Number of programs | Program	3
Number of performance obligations | Obligation	1
Number of performance obligation unsatisfied | Obligation	0
Revenue recognized from performance obligations satisfied in prior period	$ 0
Period of billing in arrears once timing of services to customers is known	1 month
Number of days for customer to make payment after being invoiced	30 days
Number of reportable segments | Segment	2
Revenues	$ 156,527,000	$ 149,930,000
Nutrition
Disaggregation Of Revenue [Line Items]
Number of sources for revenue recognition | Source	4
Description of return of obligation	Direct to consumer customers may return unopened ready-to-go products within 30 days after purchase in order to receive a refund or credit.
Return of purchase order to refund or credit, period	30 days
Purchase order canceled of delivery, period	14 days
Revenues	$ 57,567,000
Provision for estimated returns	1,400,000
Nutrition | Accrued Liabilities
Disaggregation Of Revenue [Line Items]
Reserve for estimated returns	1,300,000
Nutrition | Shipping and Handling Charges
Disaggregation Of Revenue [Line Items]
Revenues	$ 1,800,000

Revenue Recognition - Summary o

Revenue Recognition - Summary of Revenue Disaggregated by Program (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Disaggregation Of Revenue [Line Items]
Revenues	$ 214,094	$ 149,930
Healthcare
Disaggregation Of Revenue [Line Items]
Revenues	156,527	149,930
Healthcare | SilverSneakers
Disaggregation Of Revenue [Line Items]
Revenues	123,024	120,925
Healthcare | Prime Fitness
Disaggregation Of Revenue [Line Items]
Revenues	28,743	24,734
Healthcare | WholeHealth Living
Disaggregation Of Revenue [Line Items]
Revenues	4,575	4,217
Healthcare | Other
Disaggregation Of Revenue [Line Items]
Revenues	$ 185	$ 54

Revenue Recognition - Summary_2

Revenue Recognition - Summary of Revenue Disaggregated by Source (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Disaggregation Of Revenue [Line Items]
Revenues	$ 214,094	$ 149,930
Nutrition
Disaggregation Of Revenue [Line Items]
Revenues	57,567
Nutrition | Direct to Consumer
Disaggregation Of Revenue [Line Items]
Revenues	52,654
Nutrition | Retail
Disaggregation Of Revenue [Line Items]
Revenues	4,304
Nutrition | QVC
Disaggregation Of Revenue [Line Items]
Revenues	522
Nutrition | Other
Disaggregation Of Revenue [Line Items]
Revenues	$ 87

Revenue Recognition - Summary_3

Revenue Recognition - Summary of Information about Receivables, Contract Assets and Contract Liabilities from Contracts with Customers (Details) $ in Thousands	Mar. 31, 2019USD ($)
Revenue From Contract With Customer [Abstract]
Contract assets	$ 480
Contract liabilities	$ 14,997

Revenue Recognition - Summary_4

Revenue Recognition - Summary of Significant Changes in Contract Liabilities (Deferred Revenue) Balance (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)
Revenue From Contract With Customer [Abstract]
Revenue recognized that was included in the contract liability (deferred revenue) balance on March 8, 2019	$ (2,752)
Increases due to cash received for prepaid gift cards sold or unshipped food, excluding amounts recognized as revenue	$ 4,409

Revenue Recognition - Summary_5

Revenue Recognition - Summary of Revenue from Prepaid Gift Cards Expected to be Recognized in Future Related to Performance Obligation Unsatisfied or Partially Satisfied (Details) $ in Thousands	Mar. 31, 2019USD ($)
Disaggregation Of Revenue [Line Items]
Revenue, remaining performance obligation, amount	$ 12,633
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2019-04-01
Disaggregation Of Revenue [Line Items]
Revenue, remaining performance obligation, amount	$ 10,665
Revenue, remaining performance obligation, expected timing of satisfaction, period	9 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2020-01-01
Disaggregation Of Revenue [Line Items]
Revenue, remaining performance obligation, amount	$ 1,303
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2021-01-01
Disaggregation Of Revenue [Line Items]
Revenue, remaining performance obligation, amount	$ 665
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year

Revenue Recognition - Summary_6

Revenue Recognition - Summary of Revenue from Prepaid Gift Cards Expected to be Recognized in Future Related to Performance Obligation Unsatisfied or Partially Satisfied (Details 1) $ in Thousands	Mar. 31, 2019USD ($)
Revenue From Contract With Customer [Abstract]
Revenue, remaining performance obligation, amount	$ 12,633

Revenue Recognition - Additio_2

Revenue Recognition - Additional Information (Details 1)	3 Months Ended
	Mar. 31, 2019
Revenue From Contract With Customer [Abstract]
Revenue, practical expedient, financing component [true false]	true

Inventories - Additional Inform

Inventories - Additional Information (Details) $ in Millions	Mar. 31, 2019USD ($)
Inventory Disclosure [Abstract]
Reserve for excess and obsolete inventory	$ 1.3

Intangible Assets and Goodwil_2

Intangible Assets and Goodwill - Intangible Assets Subject to and Not Subject to Amortization (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 08, 2019	[1]	Dec. 31, 2018
Finite Lived Intangible Assets [Line Items]
Total intangible assets, Fair Value	$ 975,729			$ 29,049
Goodwill	780,351			$ 334,680
Nutrisystem, Inc.
Finite Lived Intangible Assets [Line Items]
Intangible assets subject to amortization, Fair Value	148,000
Total intangible assets, Fair Value	948,000
Goodwill	445,671	$ 445,671
Nutrisystem, Inc. | Tradename - Nutrisystem
Finite Lived Intangible Assets [Line Items]
Intangible assets not subject to amortization:	800,000
Tradename - Nutrisystem | Nutrisystem, Inc.
Finite Lived Intangible Assets [Line Items]
Intangible assets subject to amortization, Fair Value	$ 9,000
Intangible assets subject to amortization, Fair Value, Estimated Useful Life	15 years
Customer list | Nutrisystem, Inc.
Finite Lived Intangible Assets [Line Items]
Intangible assets subject to amortization, Fair Value	$ 125,000
Intangible assets subject to amortization, Fair Value, Estimated Useful Life	7 years
Retail customer relationship | Nutrisystem, Inc.
Finite Lived Intangible Assets [Line Items]
Intangible assets subject to amortization, Fair Value	$ 8,000
Intangible assets subject to amortization, Fair Value, Estimated Useful Life	10 years
Noncompetition agreements | Nutrisystem, Inc.
Finite Lived Intangible Assets [Line Items]
Intangible assets subject to amortization, Fair Value	$ 6,000
Intangible assets subject to amortization, Fair Value, Estimated Useful Life	5 years
[1]	Goodwill represents the excess of merger consideration over the preliminary fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Nutrisystem and synergies expected to be achieved from the combined operations of Tivity Health and Nutrisystem.

Intangible Assets and Goodwil_3

Intangible Assets and Goodwill - Additional Information (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Indefinite Lived Intangible Assets By Major Class [Line Items]
Goodwill	$ 780,351	$ 334,680
Healthcare
Indefinite Lived Intangible Assets By Major Class [Line Items]
Goodwill	334,700
Intangible assets not subject to amortization	$ 29,000

Intangible Assets and Goodwil_4

Intangible Assets and Goodwill - Change in Carrying Amount of Goodwill (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)
Goodwill And Intangible Assets Disclosure [Abstract]
Balance, January 1, 2019	$ 334,680
Acquisition of Nutrisystem	445,671
Balance, March 31, 2019	$ 780,351

Marketing Expenses - Additional

Marketing Expenses - Additional Information (Details) $ in Millions	3 Months Ended
	Mar. 31, 2019USD ($)
Marketing And Advertising Expense [Abstract]
Media expense	$ 20.3
Prepaid for future advertisements and promotions	$ 1.4

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Details) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2019USD ($)Type$ / sharesshares	Mar. 31, 2018USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Types of share based awards | Type	5
Share based awards, desription	We currently have five types of share-based awards outstanding to our employees and directors: stock options, restricted stock awards, restricted stock units, performance stock units, and market stock units.
Share-based compensation costs | $	$ 2.4	$ 1.4
Restructuring and Related Charges
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation costs | $	$ 0.1
Time-Vesting Restricted Stock Awards (Replacement Awards)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based awards, granted | shares	258,000
Share based awards, fair value | $ / shares	$ 19.42
Time-Vesting Restricted Stock Awards (Replacement Awards) | Employees | Nutrisystem
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based awards, granted | shares	258,000
Share based awards, fair value | $ / shares	$ 19.42
Time-Vesting Restricted Stock Units (Replacement Awards)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based awards, granted | shares	919,000
Share based awards, fair value | $ / shares	$ 19.42
Time-Vesting Restricted Stock Units (Replacement Awards) | Employees | Nutrisystem
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based awards, granted | shares	919,000
Share based awards, fair value | $ / shares	$ 19.42
Replacement Awards | Nutrisystem
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of replacement awards attributable to pre-combination service | $	$ 9.1
Post-combination expense expected to be recognized | $	$ 13.7
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Each of share based awards, vesting period	3 years
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Each of share based awards, vesting period	4 years

Share-Based Compensation - Summ

Share-Based Compensation - Summary of Stock Options (Details) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)$ / sharesshares
Shares [Roll Forward]
Outstanding, beginning of period (in shares) | shares	431
Exercised (in shares) | shares	(35)
Outstanding, end of period (in shares) | shares	396
Exercisable, end of period (in shares) | shares	316
Weighted-Average Exercise Price [Roll Forward]
Outstanding, beginning of period (in dollars per share) | $ / shares	$ 17.83
Exercised (in dollars per share) | $ / shares	10.70
Outstanding, end of period (in dollars per share) | $ / shares	18.46
Exercisable, end of period (in dollars per share) | $ / shares	$ 13.57
Weighted-Average Remaining Contractual Term [Abstract]
Outstanding	4 years 4 months 24 days
Exercisable	3 years 3 months 18 days
Aggregate Intrinsic Value [Abstract]
Outstanding, end of period | $	$ 1,262
Exercisable, end of period | $	$ 1,262

Share-Based Compensation - Su_2

Share-Based Compensation - Summary of Restricted Stock Awards (Details) shares in Thousands	3 Months Ended
	Mar. 31, 2019$ / sharesshares
Restricted Stock Awards
Shares [Roll Forward]
Nonvested, end of period (in shares) | shares	258
Weighted-Average Grant Date Fair Value [Roll Forward]
Nonvested, end of period (in dollars per share) | $ / shares	$ 19.42
Restricted Stock Awards Replacement Awards
Shares [Roll Forward]
Granted (in shares) | shares	258
Weighted-Average Grant Date Fair Value [Roll Forward]
Granted (in dollars per share) | $ / shares	$ 19.42

Share-Based Compensation - Su_3

Share-Based Compensation - Summary of Restricted Stock Units (Details) shares in Thousands	3 Months Ended
	Mar. 31, 2019$ / sharesshares
Restricted Stock Units (RSUs)
Shares [Roll Forward]
Nonvested, beginning of period (in shares) | shares	271
Granted (in shares) | shares	141
Vested (in shares) | shares	(68)
Nonvested, end of period (in shares) | shares	1,263
Weighted-Average Grant Date Fair Value [Roll Forward]
Nonvested, beginning of period (in dollars per share) | $ / shares	$ 24.07
Granted (in dollars per share) | $ / shares	19.42
Vested (in dollars per share) | $ / shares	11.42
Nonvested, end of period (in dollars per share) | $ / shares	$ 20.84
Restricted Stock Units (RSUs) Replacement Awards
Shares [Roll Forward]
Granted (in shares) | shares	919
Weighted-Average Grant Date Fair Value [Roll Forward]
Granted (in dollars per share) | $ / shares	$ 19.42

Share-Based Compensation - Su_4

Share-Based Compensation - Summary of Performance Stock Units (Details) - Performance Stock Units shares in Thousands	3 Months Ended
	Mar. 31, 2019$ / sharesshares
Shares [Roll Forward]
Granted (in shares) | shares	103
Nonvested, end of period (in shares) | shares	103
Weighted-Average Grant Date Fair Value [Roll Forward]
Granted (in dollars per share) | $ / shares	$ 19.42
Nonvested, end of period (in dollars per share) | $ / shares	$ 19.42

Share-Based Compensation - Su_5

Share-Based Compensation - Summary of Market Stock Units (Details) - Market Stock Units shares in Thousands	3 Months Ended
	Mar. 31, 2019$ / sharesshares
Shares [Roll Forward]
Nonvested, beginning of period (in shares) | shares	45
Granted (in shares) | shares	0
Vested (in shares) | shares	0
Forfeited (in shares) | shares	0
Nonvested, end of period (in shares) | shares	45
Weighted-Average Grant Date Fair Value [Roll Forward]
Nonvested, beginning of period (in dollars per share) | $ / shares	$ 18.25
Granted (in dollars per share) | $ / shares	0
Vested (in dollars per share) | $ / shares	0
Forfeited (in dollars per share) | $ / shares	0
Nonvested, end of period (in dollars per share) | $ / shares	$ 18.25

Income Taxes- Additional Inform

Income Taxes- Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Operating Loss Carryforwards [Line Items]
Effective tax rate	56.00%	25.10%
Increase in income tax expense	$ 2.7
Earliest Tax Year
Operating Loss Carryforwards [Line Items]
Open tax year	2015
State
Operating Loss Carryforwards [Line Items]
Increase in valuation allowance of net operating loss carryforwards	$ 1.8
Reduction in deferred tax asset related to income tax credits	$ (0.9)

Leases - Additional Information

Leases - Additional Information (Details) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2019Agreement	Dec. 31, 2018USD ($)
Lessee Lease Description [Line Items]
Number of sublease agreements | Agreement	2
Total cash receipts from subleases | $		$ 23.7
Minimum
Lessee Lease Description [Line Items]
Remaining lease terms	1 year
Maximum
Lessee Lease Description [Line Items]
Remaining lease terms	6 years

Leases - Schedule of Right-of-U

Leases - Schedule of Right-of-Use Assets and Lease Liabilities (Details) $ in Thousands	Mar. 31, 2019USD ($)
Right-of-use assets:
Operating	$ 46,578
Finance	169
Total leased assets	46,747
Current
Operating	14,762
Finance	46
Non-current
Operating	35,043
Finance	123
Total lease liabilities	$ 49,974

Leases - Schedule of Components

Leases - Schedule of Components of Lease Expense (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)
Leases [Abstract]
Amortization of leased assets	$ 12
Interest of lease liabilities	2
Operating lease cost	2,716
Short-term lease cost	33
Total lease cost before subleases	2,763
Sublease income	(1,344)
Total lease cost, net	$ 1,419

Leases - Schedule of Weighted A

Leases - Schedule of Weighted Average Remaining Term and Discount Rates (Details)	Mar. 31, 2019
Weighted Average Remaining Lease Term (years)
Operating leases, Weighted average remaining lease term (years)	3 years 7 months 6 days
Finance leases, Weighted average remaining lease term (years)	3 years 3 months 18 days
Weighted Average Discount Rate
Operating leases, Weighted average discount rate	5.40%
Finance leases, Weighted average discount rate	4.40%

Leases - Schedule of Maturities

Leases - Schedule of Maturities of Lease Liabilities (Details) $ in Thousands	Mar. 31, 2019USD ($)
Operating Leases Lease Payments
Remaining 2019	$ 12,896
2020	14,828
2021	13,361
2022	11,339
2023	1,947
2024 and thereafter	379
Total lease payments	54,750
Less: interest	(4,945)
Present value of lease liabilities	49,805
Operating Leases Sublease Receipts
Remaining 2019	(4,233)
2020	(5,667)
2021	(5,699)
2022	(5,732)
2023	(956)
Total Operating Leases Sublease Receipts	(22,287)
Operating Leases Net
Remaining 2019	8,663
2020	9,161
2021	7,662
2022	5,607
2023	991
2024 and thereafter	379
Total operating lease payments Net	32,463
Financing Leases
Remaining 2019	39
2020	52
2021	52
2022	39
Total lease payments	182
Less: interest	(13)
Present value of lease liabilities	$ 169

Leases - Schedule of Supplement

Leases - Schedule of Supplemental Cash Flow Information Related to Leases (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flow attributable to operating leases	$ (1,547)
Operating cash flow attributable to finance leases	(2)
Financing cash flows attributable to finance leases	(11)
Supplemental noncash information:
Right-of-use assets obtained in exchange for operating lease liabilities	48,972	[1]
Right-of-use assets obtained in exchange for finance lease liabilities	$ 181	[1]
[1]	No new leases were entered into during the three months ended March 31, 2019. Amounts shown are due to the adoption of ASC 842 and reflect balances as of January 1, 2019 for the Healthcare segment and as of March 8, 2019 for the Nutrition segment (i.e., the date of our acquisition of Nutrisystem).

Leases - Summary of Future Mini

Leases - Summary of Future Minimum Lease Payments Under All Non-cancelable Operating Leases (Details) $ in Thousands	Dec. 31, 2018USD ($)
Leases [Abstract]
2019	$ 4,022
2020	2,040
2021	910
2022	827
2023	136
Total minimum lease payments	$ 7,935

Debt - Summary of Debt, Net of

Debt - Summary of Debt, Net of Unamortized Deferred Loan Costs And Original Issue Discount (Details) - USD ($) $ in Thousands		Mar. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Debt, net of unamortized original issue discount		$ 1,165,000	$ 30,646
Less: deferred loan costs and original issue discount ("OID")		(53,160)
Total debt		1,111,840	30,646
Less: current portion		(44,900)	(57)
Long-term debt		1,066,940	30,589
Term Loan A
Debt Instrument [Line Items]
Debt, net of unamortized original issue discount		341,000
Term Loan B
Debt Instrument [Line Items]
Debt, net of unamortized original issue discount		$ 824,000
Delayed Draw Term Loan
Debt Instrument [Line Items]
Debt, net of unamortized original issue discount			25,000
Revolving Credit Facility
Debt Instrument [Line Items]
Debt, net of unamortized original issue discount			5,450
Capital Lease Obligations and Other
Debt Instrument [Line Items]
Debt, net of unamortized original issue discount	[1]		$ 196
[1]	Prior to the adoption of ASC 842 on January 1, 2019, our capital leases were recorded as part of debt. Beginning on January 1, 2019, they are classified as financing leases under ASC 842 and are recorded as part of lease liabilities.

Debt - Credit Facility - Additi

Debt - Credit Facility - Additional Information (Details) - USD ($)	Mar. 08, 2019	Mar. 31, 2019
Prior Credit Agreement
Line Of Credit Facility [Line Items]
Initiation date		Apr. 21, 2017
Credit Agreement
Line Of Credit Facility [Line Items]
Initiation date		Mar. 8, 2019
Credit Agreement | Federal Funds Rate
Line Of Credit Facility [Line Items]
Basis spread on variable rate	0.50%
Credit Agreement | One-Month LIBOR
Line Of Credit Facility [Line Items]
Basis spread on variable rate	1.00%
Credit Agreement | Minimum
Line Of Credit Facility [Line Items]
Unused commitment fee percentage	0.25%
Credit Agreement | Minimum | LIBOR
Line Of Credit Facility [Line Items]
Variable rate basis	0.00%
Credit Agreement | Maximum
Line Of Credit Facility [Line Items]
Unused commitment fee percentage	0.50%
Credit Agreement | Revolving Credit Facility
Line Of Credit Facility [Line Items]
Maximum borrowing capacity	$ 125,000,000
Maturity date		Mar. 8, 2024
Credit Agreement | Revolving Credit Facility | Minimum | LIBOR
Line Of Credit Facility [Line Items]
Margin rate	3.75%
Credit Agreement | Revolving Credit Facility | Minimum | Base Rate
Line Of Credit Facility [Line Items]
Margin rate	2.75%
Credit Agreement | Revolving Credit Facility | Maximum | LIBOR
Line Of Credit Facility [Line Items]
Margin rate	4.25%
Credit Agreement | Revolving Credit Facility | Maximum | Base Rate
Line Of Credit Facility [Line Items]
Margin rate	3.25%
Credit Agreement | Swingline Sub Facility
Line Of Credit Facility [Line Items]
Maximum borrowing capacity	$ 35,000,000
Maturity date		Mar. 8, 2024
Credit Agreement | Letters of Credit Sub Facility
Line Of Credit Facility [Line Items]
Maximum borrowing capacity	50,000,000
Credit Agreement | Term Loan Facility A
Line Of Credit Facility [Line Items]
Debt instrument, face amount	$ 350,000,000
Periodic principal payment as percentage of aggregate principal amount	2.50%
Maturity date		Mar. 8, 2024
Credit Agreement | Term Loan Facility A | LIBOR
Line Of Credit Facility [Line Items]
Margin rate	4.25%
Credit Agreement | Term Loan Facility A | Base Rate
Line Of Credit Facility [Line Items]
Margin rate	3.25%
Credit Agreement | Term Loan Facility B
Line Of Credit Facility [Line Items]
Debt instrument, face amount	$ 830,000,000
Periodic principal payment as percentage of aggregate principal amount	0.75%
Maturity date		Mar. 8, 2026
Credit Agreement | Term Loan Facility B | LIBOR
Line Of Credit Facility [Line Items]
Margin rate	5.25%
Credit Agreement | Term Loan Facility B | Base Rate
Line Of Credit Facility [Line Items]
Margin rate	4.25%
Credit Agreement | Uncommitted Incremental Accordion Facility | Minimum
Line Of Credit Facility [Line Items]
Maximum borrowing capacity	$ 125,000,000
Percentage of consolidated EBITDA requirement	50.00%

Debt - Cash Convertible Notes -

Debt - Cash Convertible Notes - Additional Information (Details) - $ / shares	Oct. 01, 2018	Mar. 31, 2019	Jul. 31, 2013
Debt Instrument [Line Items]
Number of trading days, warrants automatically exercised on a pro rata basis	160 days
Number of warrants are automatically exercised on each trading day	48,000
Common Stock
Debt Instrument [Line Items]
Common stock shares issued related to automatic exercise of warrants		0
Common Stock | Warrants | Cash Convertible Notes Hedge
Debt Instrument [Line Items]
Shares issued upon conversion of debt			7,700,000
1.50% Cash Convertible Senior Notes Due 2018
Debt Instrument [Line Items]
Warrants strike price (in dollars per share)			$ 25.95

Commitments and Contingencies -

Commitments and Contingencies - Additional Information - (Details)	Nov. 06, 2017Lawsuit
Commitments And Contingencies Disclosure [Abstract]
Number of lawsuits filed	4

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Revolving Credit Facility
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Line of credit	$ 0
Carrying Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Cash and cash equivalents	18,800,000
Cash Convertible Notes Hedges and Cash Conversion Derivative
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Assets and liabilities measured at fair value on a recurring basis	0	$ 0
Term Loans
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Debt instrument fair value	1,146,000,000
Debt instrument carrying amount	$ 1,165,000,000

Restructuring and Related Cha_2

Restructuring and Related Charges - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2019	Mar. 31, 2019
Restructuring Cost And Reserve [Line Items]
Restructuring and related charges		$ 1,591
2019 Restructuring Plan
Restructuring Cost And Reserve [Line Items]
Restructuring and related charges		1,600
Total annualized savings		7,200
Healthcare | 2019 Restructuring Plan
Restructuring Cost And Reserve [Line Items]
Restructuring and related charges		1,000
Total annualized savings		3,500
Nutrition | 2019 Restructuring Plan
Restructuring Cost And Reserve [Line Items]
Restructuring and related charges		600
Total annualized savings		$ 3,700
Nutrition | 2019 Restructuring Plan | Scenario, Forecast
Restructuring Cost And Reserve [Line Items]
Severance and other employee-related costs	$ 800

Earnings Per Share - Reconcilia

Earnings Per Share - Reconciliation of the Numerator and Denominator of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Numerator [Abstract]
Net income	$ 4,214	$ 21,336
Denominator [Abstract]
Shares used for basic income per share	42,745	39,783
Effect of dilutive stock options and restricted stock units outstanding [Abstract]
Shares used for diluted income per share	43,183	43,589
Earnings per share: [Abstract]
Basic	$ 0.10	$ 0.54
Diluted	$ 0.10	$ 0.49
Non-Qualified Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Dilutive securities outstanding not included in the computation of earnings (loss) per share because their effect is anti-dilutive (in shares)	80
Restricted Stock Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Dilutive securities outstanding not included in the computation of earnings (loss) per share because their effect is anti-dilutive (in shares)	56	14
Restricted Stock Awards
Effect of dilutive stock options and restricted stock units outstanding [Abstract]
Effect of dilutive stock options and restricted stock units outstanding (in shares)	16
Non-Qualified Stock Options
Effect of dilutive stock options and restricted stock units outstanding [Abstract]
Effect of dilutive stock options and restricted stock units outstanding (in shares)	127	312
Restricted Stock Units
Effect of dilutive stock options and restricted stock units outstanding [Abstract]
Effect of dilutive stock options and restricted stock units outstanding (in shares)	292	405
Performance Stock Units
Effect of dilutive stock options and restricted stock units outstanding [Abstract]
Effect of dilutive stock options and restricted stock units outstanding (in shares)	3
Market Stock Units
Effect of dilutive stock options and restricted stock units outstanding [Abstract]
Effect of dilutive stock options and restricted stock units outstanding (in shares)		533
Warrants Related to Cash Convertible Notes
Effect of dilutive stock options and restricted stock units outstanding [Abstract]
Effect of dilutive stock options and restricted stock units outstanding (in shares)		2,556

Segment Information - Additiona

Segment Information - Additional Information (Details)	3 Months Ended
	Mar. 31, 2019Segment
Segment Reporting [Abstract]
Number of reportable segments	2

Segment Information - Schedule

Segment Information - Schedule of Each Segment's Profit (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Segment Reporting Information [Line Items]
Revenues	$ 214,094	$ 149,930
Adjusted EBITDA	39,473
Acquisition and integration costs	17,052
Restructuring and related charges	1,591
Interest expense	7,666	3,454
Depreciation and amortization	3,582	1,123
Income before income taxes	9,582	28,493
Total assets	2,070,588		$ 482,079
Healthcare
Segment Reporting Information [Line Items]
Revenues	156,527	$ 149,930
Adjusted EBITDA	26,129
Total assets	456,017
Nutrition
Segment Reporting Information [Line Items]
Revenues	57,567
Adjusted EBITDA	13,344
Total assets	$ 1,614,571